Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 11,520 shares at $19.05 ($219K) on 2025-01-02, disclosed to the SEC on 2025-01-06.
Scheduled sale ($219k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |